Dr. Creasy aims to understand how genetic variation affects liver lipid metabolism, and how alterations in liver metabolism lead to chronic diseases. Changes in lipid metabolism are common in numerous diseases, including cardiovascular disease, metabolic syndrome, Diabetes, Alzheimer’s Disease, and many cancers. Her research goals are to understand the genetic and regulatory mechanisms of liver lipid metabolism that become altered in the progression of cardiometabolic diseases, and to develop methods to detect these alterations to be used for earlier detection and improved treatment options. The Creasy Lab will use human genetics to guide investigations into dysregulated liver lipid metabolism and the effects on cardiometabolic diseases with the goal of developing personalized nutrition approaches to treating patients.

With the growing obesity epidemic and related cardiometabolic illnesses, it is imperative to develop comprehensive methods to evaluate and treat patients. By combining insights from human genetics with advanced research approaches in molecular metabolism, we can develop better strategies for providing precision nutrition care.


  • PhD, University of Kentucky,
  • Post-Baccalaureate Study: Human Nutrition and Dietetics, University of North Carolina- Greensboro,
  • BS, Greensboro College,


Dr. Creasy is the course director for NUTR 6020, Advanced Micronutrient Metabolism, and NUTR 6100, Omics of Nutrition Science, both of which are offered through the Master of Science in Nutrition Science (MSNS) program. She has opportunities for lab-based research and independent study with students at all education levels.


Dr. Creasy’s research program focuses on understanding the genetics of metabolic diseases, and how molecular investigations can inform precision nutrition recommendations. She uses cutting edge techniques including single-cell RNA sequencing and metabolomics of human patient samples to characterize transcriptional and metabolic changes in people with various stages of metabolic-associated steatotic liver disease and related comorbidities.

Opportunities to Learn and Collaborate at Penn Nursing

Dr. Creasy actively collaborates with multiple centers and interdisciplinary teams across Penn and other institutions to conduct translational metabolic disease research.

Selected Publications

  • Vell MS, Loomba R, Krishnan A, et al. Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality. JAMA Netw Open. 2023;6(6):e2320222. doi:10.1001/jamanetworkopen.2023.20222

    Include article hyperlink: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2806370

  • Seeling, KS, Hehl, L, Vell, MS, Rendel, MD, Creasy, KT, Trautwein, C, et al. Comorbidities, biomarkers and cause specific mortality in patients with irritable bowel syndrome: a phenome-wide association study. United European Gastroenterol J. 2023; 11( 5): 458– 70. https://doi.org/10.1002/ueg2.12397

    Link: https://onlinelibrary.wiley.com/doi/full/10.1002/ueg2.12397

  • Scorletti E, Creasy KT, Vujkovic M, Vell M, Zandvakili I, Rader DJ, Schneider KM, Schneider CV. Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2022 Jun 1;117(6):927-930. doi: 10.14309/ajg.0000000000001726. Epub 2022 Mar 14. PMID: 35288522; PMCID: PMC9177739.

    Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177739/

  • Vujkovic, M., Ramdas, S., Lorenz, K.M. et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat Genet54, 761–771 (2022). https://doi.org/10.1038/s41588-022-01078-z

    Link: https://www.nature.com/articles/s41588-022-01078-z

View all publications